

Editorial: Cardiovascular cell senescence in aging and disease

Original

Editorial: Cardiovascular cell senescence in aging and disease / Gaetano, C., Pesce, M., Beltrami, A.P., Capogrossi, M.C.. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - 10:(2023).
[10.3389/fcvm.2023.1177395]

Availability:

This version is available at: 11583/2999780 since: 2025-05-02T13:52:11Z

Publisher:

Frontiers Media S.A.

Published

DOI:10.3389/fcvm.2023.1177395

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)



OPEN ACCESS

EDITED AND REVIEWED BY
Ngan F Huang,
Stanford University, United States

*CORRESPONDENCE

Carlo Gaetano
✉ carlo.gaetano@icsmaugeri.it
Maurizio C. Capogrossi
✉ mcapogr1@jhmi.edu

SPECIALTY SECTION

This article was submitted to Cardiovascular
Biologics and Regenerative Medicine, a section
of the journal Frontiers in Cardiovascular
Medicine

RECEIVED 01 March 2023

ACCEPTED 09 March 2023

PUBLISHED 24 March 2023

CITATION

Gaetano C, Pesce M, Beltrami AP and
Capogrossi MC (2023) Editorial: Cardiovascular
cell senescence in aging and disease.
Front. Cardiovasc. Med. 10:1177395.
doi: 10.3389/fcvm.2023.1177395

COPYRIGHT

© 2023 Gaetano, Pesce, Beltrami and
Capogrossi. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Editorial: Cardiovascular cell senescence in aging and disease

Carlo Gaetano^{1*}, Maurizio Pesce², Antonio P. Beltrami³
and Maurizio C. Capogrossi^{4,5*}

¹Laboratorio di Epigenetica, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ²Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan, Italy, ³Dipartimento di Medicina, Istituto di Anatomia Patologica Universitaria, Azienda Ospedaliero Universitaria "S. Maria della Misericordia", Udine, Italy, ⁴Division of Cardiology, Johns Hopkins University, Baltimore, MD, United States, ⁵Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States

KEYWORDS

aging, senescence, signal transduction, transcriptomic, cardiovascular disease

Editorial on the Research Topic

Cardiovascular cell senescence in aging and disease

There is no uniform consensus on the relationships between age and aging. For example, the Medical Subject Heading definition in Medline defines aging as "The gradual, irreversible changes in structure and function of an organism that occur as a result of the passage of time." However, such a definition has severe flaws because it fails to include the broader context of development in early life, plasticity, and regeneration. For example, in the cardiovascular system, the plasticity of the blood vessels, including their ability to regenerate in response to a variety of cues, is in contrast to the minimal regenerative ability of the myocardium; and cardiovascular coupling increases the complexity of such an articulated organismal system in response to aging. In this context, the impact of the aging process and the associated cellular senescence makes it challenging to predict the impact of aging on the different cardiovascular components (1). Moreover, the concept that aging related to cellular senescence is only a function of time is misleading, at least for the cardiovascular system. Consolidated evidence suggests that the combination of risk conditions can have a variable impact on cellular senescence, translating into accelerated biological aging.

It is noteworthy that the risk of developing cardiovascular disease (CVD) is primarily (75%–90%) explained by the presence or absence of traditional CVD risk factors (2). An increase in age is a well-known traditional risk factor generally considered non-modifiable. In 2021, the American Heart Association (AHA) reported that the incidence of CVD in US men and women is ~40% from 40 to 59 years; the incidence rises in the 60–79-year-old age group to 77.5% of males and 75.4% of females; in the 80 plus-year-old age group, CVD incidence reaches 89.4% in males and 90.8% in females (https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2021-Heart-and-Stroke-StatUpdate/2021_Stat_Update_factsheet_Older_and_CVD.pdf).

The burden of CVD is directly related to the increased mortality, morbidity, and frailty in affected individuals, which also translates to significant overall healthcare costs (3). According to the World Population Prospects 2022 (<https://population.un.org/wpp/>), the share of the global population aged 65 years or above is projected to rise from 10 percent

in 2022 to 16 percent in 2050. By then, 1 in 6 people worldwide will be over 65 with a clear potential of developing cardiovascular accidents just because of age.

In this scenario, investigating the molecular mechanisms associated with cardiovascular aging and its pathophysiological consequences is of the utmost relevance. The special issue of *Frontiers in Cardiovascular Medicine* dedicated to “Cardiovascular Cell Senescence in Aging and Disease” goes well in this direction.

In a first experimental article, Wang et al. experimentally explored the molecular role of the poorly characterized E3 ubiquitin ligase named mitsugumin 53 (MG53) in regulating necroptosis following ischemia-reperfusion injury (I/R) injury to the heart and the involvement of reactive oxygen species (ROS) in MG53-mediated cardioprotection. The authors conclude that appropriate modulation of ROS is crucial in limiting the consequences of ischemic cardiac damage.

In another study, Gou et al. applied single-cell transcriptomics to understand how cellular senescence might negatively impact the mouse vascular endothelium. They found that ribosome biogenesis, inflammation, apoptosis, and angiogenesis-related genes and pathways changed with age and that the transcription factor *Jun* could be implicated in this process.

In the same issue, a review from Liu et al. addresses the anti-aging properties of physical exercise. Here, the authors claim that there is substantial evidence that changes in the autonomic nervous system and arterial stiffness play an essential role in the development of cardiovascular disease during the aging process. In this context, exercise is known to be effective in improving autonomic regulation and arterial vascular compliance, but differences in the type and intensity of exercise can have varying degrees of impact on vascular regulatory responses and autonomic function.

Finally, in a valuable contribution from Dominga Iacobazzi of Paolo Madeddu’s group (Iacobazzi et al.), it is proposed that patients with congenital heart disease (CHD) suffer from multiple

repeated stresses from an early stage life, which wears out homeostatic mechanisms and cause premature cardiac aging.

In conclusion, consolidating cell senescence and aging as essential effectors of cardiovascular risk, this special issue of *Frontiers in Cardiovascular Medicine* emphasizes still underestimated aspects. The role of ubiquitination, transcription factors, exercise, and congenital heart disease are only apparently heterogeneous. They are different aspects of the same problem, namely, the effect of aging progression on the cardiovascular system function. Potential and novel strategies to reduce the negative impact of aging as a risk factor for heart disease may arise from reading these contributions.

Author contributions

CG, MP, APB and MCC wrote and revised the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Dhingra R, Vasani RS. Age as a risk factor. *Med Clin North Am.* (2012) 96(1):87–91. doi: 10.1016/j.mcna.2011.11.003
2. Vasani RS, Sullivan LM, Wilson PW, Sempos CT, Sundstrom J, Kannel WB, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Ann Intern Med.* (2005) 142(6):393–402. doi: 10.7326/0003-4819-142-6-200503150-00005
3. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. *Clin Geriatr Med.* (2009) 25(4):563–77. doi: 10.1016/j.cger.2009.07.007